Lupus nephritis is a severe cause of acute kidney injury and an important cause of end-stage renal failure in some regions such as Asia. It is characterised by aberrant innate and adaptive immune responses, autoantibody production and their deposition in the kidney parenchyma, triggering complement activation, increased proliferation of resident renal cells and upregulation of pro-inflammatory molecules leading to inflammatory cell infiltration, all of which culminate in the destruction of normal nephrons and their replacement by fibrous tissue. Anti-dsDNA antibodies are specific to SLE and their level often correlates with disease activity. Apart from mediating pathogenic process through the formation of immune complexes, there is evidence that pathogenic anti-dsDNA antibodies can bind to resident renal cells and induce downstream inflammatory and fibrotic processes. Though clinically effective, current treatment for lupus nephritis entails the use of non-specific immunosuppressive agents and the anti-inflammatory action of high-dose corticosteroids. The clinical and histological impact of novel biologics targeting pro-inflammatory molecules remain to be fully defined. Insight into the underlying mechanisms that induce inflammatory and fibrotic processes in the kidney in lupus nephritis could offer opportunities for novel therapeutic options to improve clinical outcome. This lecture will discuss recent advances in the understanding of pathogenic mechanisms leading to inflammation and fibrosis in the kidney in lupus nephritis, with particular focus on the contribution of resident renal cells.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.